Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.64 USD | -.--% | -2.94% | -61.60% |
05-30 | SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer | CI |
05-21 | FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.60% | 24.36M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.67% | 12.27B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- Chardan Capital Adjusts SAB Biotherapeutics' Price Target to $7 from $10, Keeps Buy Rating